Wednesday, July 8, 2026

pharma · Rectal Cancer · Fanconi Anemia · RCKT

Rocket Pharmaceuticals

Rocket Pharmaceuticals is a pharma organization headquartered in Cranbury, USA. It trades on NYSE under ticker RCKT. Primary therapeutic focus areas include Rectal Cancer, Fanconi Anemia, Danon Disease, PKP2 Arrhythmogen

9 Cedarbrook Dr, Cranbury, New Jersey 08512, US HQ
2015 Founded
226 Employees
Public company Type
RCKT · NYSE Ticker
Company details
Status
Public
HQ
9 Cedarbrook Dr, Cranbury, New Jersey 08512, US
Founded
2015
Employees
226
Programs
11
Drugs
10
Patents
1
Clinical program

RP-A701-0125

Phase 1 · gene therapy · Dilated Cardiomyopathy (DCM)

RP-A701-0125 for Dilated Cardiomyopathy (DCM) is a Phase 1 program (gene_therapy) at Rocket Pharmaceuticals B.V. with 1 ClinicalTrials.gov record(s).

Internal code RP-A701-0125

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Rocket Pharmaceuticals B.V.
Phase
Phase 1
Modality
gene_therapy
Indication
Dilated Cardiomyopathy (DCM)
Status
active
Trials
1